Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2006-9-25
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Anti-HIV Agents, http://linkedlifedata.com/resource/pubmed/chemical/Antidepressive Agents, http://linkedlifedata.com/resource/pubmed/chemical/Antiparkinson Agents, http://linkedlifedata.com/resource/pubmed/chemical/Apomorphine, http://linkedlifedata.com/resource/pubmed/chemical/Azabicyclo Compounds, http://linkedlifedata.com/resource/pubmed/chemical/Carbamates, http://linkedlifedata.com/resource/pubmed/chemical/Central Nervous System Agents, http://linkedlifedata.com/resource/pubmed/chemical/Cytochrome P-450 Enzyme System, http://linkedlifedata.com/resource/pubmed/chemical/Hypnotics and Sedatives, http://linkedlifedata.com/resource/pubmed/chemical/Indenes, http://linkedlifedata.com/resource/pubmed/chemical/Oligopeptides, http://linkedlifedata.com/resource/pubmed/chemical/Phosphoric Acid Esters, http://linkedlifedata.com/resource/pubmed/chemical/Piperazines, http://linkedlifedata.com/resource/pubmed/chemical/Pyridines, http://linkedlifedata.com/resource/pubmed/chemical/Sulfonamides, http://linkedlifedata.com/resource/pubmed/chemical/Thiophenes, http://linkedlifedata.com/resource/pubmed/chemical/atazanavir, http://linkedlifedata.com/resource/pubmed/chemical/duloxetine, http://linkedlifedata.com/resource/pubmed/chemical/fosamprenavir, http://linkedlifedata.com/resource/pubmed/chemical/ramelteon, http://linkedlifedata.com/resource/pubmed/chemical/zopiclone
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1527-4160
pubmed:author
pubmed:issnType
Print
pubmed:volume
12
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
312-6
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:16998419-Anti-HIV Agents, pubmed-meshheading:16998419-Antidepressive Agents, pubmed-meshheading:16998419-Antiparkinson Agents, pubmed-meshheading:16998419-Apomorphine, pubmed-meshheading:16998419-Azabicyclo Compounds, pubmed-meshheading:16998419-Carbamates, pubmed-meshheading:16998419-Central Nervous System Agents, pubmed-meshheading:16998419-Cytochrome P-450 Enzyme System, pubmed-meshheading:16998419-Drug Approval, pubmed-meshheading:16998419-Drug Interactions, pubmed-meshheading:16998419-Humans, pubmed-meshheading:16998419-Hypnotics and Sedatives, pubmed-meshheading:16998419-Indenes, pubmed-meshheading:16998419-Long QT Syndrome, pubmed-meshheading:16998419-Mental Disorders, pubmed-meshheading:16998419-Oligopeptides, pubmed-meshheading:16998419-Phosphoric Acid Esters, pubmed-meshheading:16998419-Piperazines, pubmed-meshheading:16998419-Psychopharmacology, pubmed-meshheading:16998419-Pyridines, pubmed-meshheading:16998419-Sulfonamides, pubmed-meshheading:16998419-Thiophenes
pubmed:year
2006
pubmed:articleTitle
Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: Part II.
pubmed:affiliation
Department of Psychiatry, University of Kansas School of Medicine-Wichita, Wichita, Kansas, USA.
pubmed:publicationType
Journal Article, Review